Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 42%
Sell 8%
Strong Sell 0%

Bulls say

Incyte's stock outlook is bolstered by a 10% year-over-year growth in Jakafi demand across all indications, supported by stable channel inventory levels. The company's first dermatology product, Opzelura, also demonstrated significant growth, achieving revenues of $188 million, indicating strong patient demand for both atopic dermatitis and vitiligo treatments. Furthermore, Incyte raised its fiscal year 2025 revenue guidance to $4.23 billion - $4.32 billion, driven by improved forecasts for Jakafi and other oncology products, showcasing robust operational execution and a positive sentiment in the broader market.

Bears say

Incyte faces significant downside risks that threaten its financial stability, primarily stemming from eroding pricing power for its leading drug, Jakafi, and poor performance in its earlier-stage pipeline. Clinical and regulatory setbacks related to Jakafi combinations could exacerbate these challenges, leading to potential declines in revenue and diminished market competitiveness. Furthermore, risks such as poor drug uptake, reimbursement obstacles, heightened competition, and safety concerns surrounding marketed products contribute to a negative outlook for Incyte's financial performance.

Incyte (INCY) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 42% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 12 analysts, Incyte (INCY) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.